Comparison · NCT00499863-4feefe56
Methylphenidate Transdermal System vs Placebo (PTS): Improvement in Parent Global Assessment (PGA) Score
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Methylphenidate Transdermal System vs Placebo (PTS): Improvement in Parent Global Assessment (PGA) Score. Trial comparisons, record NCT00499863-4feefe56. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00499863-4feefe56
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.531 | 0.45 | 0.611 | wilson | |
| Risk in group 2 | 0.208 | 0.131 | 0.316 | wilson | |
| Risk difference, group 1 minus group 2 | 0.323 | 0.188 | 0.435 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2.55 | 1.59 | 4.11 | log | |
| Odds ratio, group 1 over group 2 | 4.31 | 2.24 | 8.31 | log | |
| Number needed to treat, for one more participant with the outcome on Methylphenidate Transdermal System than on Placebo (PTS) | 3.09 | 2.3 | 5.31 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Methylphenidate Transdermal System | Methylphenidate Transdermal System Patch | 76 | 143 | OG000 |
| Group 2 | Placebo (PTS) | Placebo Transdermal System | 15 | 72 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Improvement in Parent Global Assessment (PGA) Score
- Description
Parent Global Assessment (PGA) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement includes a score of 1 (very much improved) or 2 (much improved) on the scale.
- Time frame
- up to 7 weeks
- Population
- ITT
Source ClinicalTrials.gov
Trial
- Title
- Evaluate the Efficacy &Safety of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD
- NCT number
- NCT00499863
- Phases
- PHASE3
- Conditions
- ADHD
- Interventions
- methylphenidate transdermal system, Placebo
- Lead sponsor
- Noven Therapeutics
- Results first posted
- 2009-06-11
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00499863?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00499863-4feefe56